keyboard_arrow_up

Top 50 Big Pharma Partnering and M&A Deal Trends

Top 50 Big Pharma Partnering and M&A Deal Trends is a new market research publication announced by Reportstack. This report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.
 
Top 50 Big Pharma Partnering and M&A Deal Trends provides the user with the following key benefits:
 
Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2009 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
 
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. This premier report provides all the information you require to better understand big pharma partnering.
 
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
 
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each big pharma companies dealmaking trends over the last four years.
 
This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by bigpharma and their partners.
 
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. The initial chapters of this report provide an orientation of big pharma’s dealmaking and business activities.
 
This report provides an introduction to the report, lists the top 50 leading big pharma companies based on 2013 pharmaceutical revenues and dealmaking activity since 2009, reviews the top partnering and M&A deals of 2009-2014 according to reported deal size. This report provides a summary on best practice on how to submit an opportunity to big pharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.
 
This report lists forthcoming partnering events where valuable face to face meetings with big pharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.
 
One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.
 
Understanding the flexibility of a prospective partners’ negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
                                                             
This data driven report contains over 3,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
 In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
In summary, the report provides the reader with the tools necessary to make successful contact with the right big pharma partners effectively and efficiently.

To view the table of contents and know more details please visit Top 50 Big Pharma Partnering and M&A Deal Trends.